WuXi AppTec acquisition enhances its biometrics services for clinical development6 May 2019
Acquisition will help customers to shorten time-to-market of new drugs.
WuXi AppTec has acquired Pharmapace, a US-based clinical research services company with expertise of providing high-quality biometrics services for all phases of clinical trials, regulatory submissions, and post-marketing support. Upon the closing of this acquisition, Pharmapace will become a wholly-owned subsidiary of WuXi Clinical - the clinical CRO arm of WuXi AppTec - and will continue to focus on growing its core biometrics competences and integrate with WuXi Clinical's other clinical development services.
Founded in 2013 in San Diego, California, Pharmapace provides a full range of biometrics services for all phases of clinical trials, including clinical and statistical programming, data management, biostatistics, clinical data integration, and medical writing with clients in North America, Europe and Asia. With this acquisition, WuXi Clinical expanded its biometrics capabilities in the US and Europe. By integrating Pharmapace and WuXi Clinical China based biometrics teams, the company will be able to provide its global customers with efficient and cost-effective biometrics service essentially round the clock.
With the addition of Pharmapace, WuXi Clinical collectively has over 850 employees located in China and the US, together with its close partners in Europe, Asia Pacific, the company can provide customers full clinical development services, as well as functional service provider (FSP) worldwide. China's recent regulatory reforms that embrace overseas trial data provide an unprecedented opportunity for innovators around the world to accelerate and integrate clinical development both regionally and globally through the WuXi Clinical organization.
"Pharmapace is excited to join WuXi AppTec, a world-class organization with superior leadership and long history of success, a like-minded focus with a customer-centric approach, as well as a vision to enable every company to discover and develop drugs for the patients around the world. This combination now allows us to leverage WuXi AppTec's vast resources to offer customers a truly global solution from preclinical development to clinical development and regulatory submission," said Dr Larry Shen, President and CEO of Pharmapace.
"We are very pleased to welcome Pharmapace to WuXi AppTec. Larry and his leadership team have built a highly reputable biometrics organization in the US," said Edward Hu, Co-CEO of WuXi AppTec. "This acquisition further enhances WuXi Clinical's drug development expertise and biometrics capabilities and lays the foundation for the creation of an integrated global biometrics service platform to efficiently and cost effectively provide customers seamless biometrics services globally. Together, we are able to shorten time-to-market of new drugs and to achieve the dream that 'every drug can be made and every disease can be treated'."
New microbial air sampler addresses continuous monitoring
14 Nov 2019
The device supports the new EU GMP Annex 1 requirements.Read more
GVK Bio continues to see growth tailwinds for 2020 thanks to a ‘crescendo of factors’
13 Nov 2019
China-US trade challenges has led to de-risking by pharma companies.Read more
Winners of the 16th Pharma Awards
11 Nov 2019
Companies and individuals from across the whole pharma supply chain recognised for their excellence and commitment.Read more
CDMOs to benefit from rising BTDs, orphan drugs and fast track status therapies
8 Nov 2019
But personalized medicines will require new logistics and manufacturing systems.Read more
SGH Healthcaring unveils its new asthma spacer device
8 Nov 2019
Zephyr's revolutionary new design improves drug administration and simplifies treatment delivery for better observance.Read more
Recipharm expands Indian injectable dosage form capabilities
7 Nov 2019
Partnership will combine capabilities and expertise in Europe and India to build a new facility dedicated to injectable formulations to supply demand from Europe and overseas territories.Read more
Aptar acquires a leader in drug delivery training devices and patient onboarding
6 Nov 2019
Acquisition reflects movement of treatments being administered by patients at home rather than by healthcare providers.Read more
Europe predicted to surpass the US in biologic manufacturing capacity by 2023
6 Nov 2019
Demand for biological manufacturing is growing faster than capacity growth.Read more
SP acquires Spain based global provider of complete sterile filling lines
5 Nov 2019
Company's strategic move reflects its expectation of short-run aseptic liquid filling to continue to drive pharmaceutical growth.Read more
Legacy recruits heavily to meet growing steriles demand
5 Nov 2019
Company to reach 250 employees by year end to meet growing drug product manufacturing demand.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation